Project Grant R01CA301124
Award Date 9/8/25
Completion Date 7/31/29
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports the development of an automated multimodal, multiscale algorithm for cervical cancer screening in low- and middle-income countries (LMICs). The $104,278 award, granted on January 11, 2026, will fund the following key objectives: Design a multimodal image registration algorithm to spatially correlate and combine information from widefield colposcope images and...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
- This $663,383 Project Grant was awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Georgetown University on August 1, 2025. The project aims to conduct proactive outreach and provide streamlined genetic testing for prostate cancer survivors. This research is crucial to customize cancer treatment and guide prevention, as germline pathogenic variants in DNA-repair genes are common and clinically significant in prostate cancer patients. Despite clear...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated...
- This federal Project Grant award of $163,500.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to develop new therapies for diffuse-type gastric cancer (DGAC). The primary awardee, The University of Texas MD Anderson Cancer Center, aims to unravel the mechanisms of DGAC tumorigenesis and apply that knowledge to lay a foundation for DGAC therapy development. Key objectives include determining the impact of drug candidates on DGAC stemness,...
- The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...
- The National Cancer Institute (NCI) awarded a $200,000 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, awarded on September 15, 2023, supports research to develop novel therapeutic approaches to remediate radiotherapy-induced bone necrosis in oropharyngeal cancer patients, particularly among African-American populations who...